Navigation Links
Henry Ford Hospital study: hVISA linked to high mortality
Date:9/12/2010

A MRSA infection with a reduced susceptibility to the potent antibiotic drug vancomycin is linked to high mortality, according to a Henry Ford Hospital study.

Researchers found that patients who contracted a MRSA infection with heteroresistance, called hVISA, stayed in the hospital longer, were more likely to have the infection return after 90 days, and were twice as likely to die from it after 90 days than patients who do not have hVISA.

The study is being presented Sunday at the 50th annual Interscience Conference on Antimicrobial Agents and Chemotherapy in Boston.

"Based on our findings, we recommend that hospitals consider routine testing for hVISA," says Katherine Reyes, M.D., a Henry Ford Hospital Internal Medicine physician and the study's lead author. "It remains controversial how differently we will manage these patients upfront. Close follow-up on these patients to make sure their infection is resolved or controlled may save lives."

MRSA, or Methicillin-resistant Staphylococcus aureus, is a bacterium that is resistant to common antibiotics like penicillin. It can cause skin, bloodstream and surgical wound infections and pneumonia. The majority of infections occur among patients in hospitals or other health care settings, though a growing number of infections are being acquired by otherwise healthy people outside those settings.

MRSA strains can be resistant to many drugs, though they are typically susceptible to the antibiotic vancomycin. MRSA infections are often treated with vancomycin administered intravenously.

The study followed 521 patients with MRSA bloodstream infections who were admitted between January 2006 to September 2009 to Henry Ford, an 805-bed tertiary care hospital, education and research complex in Detroit. These infections were screened for heteroresistance, and 19 hVISA cases were identified.

Dr. Reyes and researchers then compared characteristics and outcomes of the 19 hVISA patients against 19 non-hVISA patients, eliminating such factors as age, source of infection and level of sickness. The results:

  • Six hVISA patients died within 30 days compared to three non-hVISA patients.
  • Twelve hVISA patients died within 90 days compared to six non-hVISA patients.
  • Five hVISA patients saw their infection return after 90 days compared to zero for non-hVISA patients.
  • hVISA patients stayed on average four more days in the hospital than non-hVISA patients.
  • hVISA patients were more likely to have received vancomycin in the past.


'/>"/>

Contact: David Olejarz
dolejar1@hfhs.org
313-874-4094
Henry Ford Health System
Source:Eurekalert

Related medicine news :

1. The Henry Ford Production System LEAN training for health care
2. Henry Ford Hospital study: Donor Risk Index does not impact outcomes on a small scale
3. Healthy U Chosen as Exclusive Concessions Provider for McHenry's 1st Annual Kicks 4 Kids Youth Charity Soccer Tournament
4. Sung-Cheng (Henry) Huang receives 2010 Benedict Cassen Prize for Research in Nuclear Medicine
5. Henry Gabelnick receives lifetime achievement award
6. Henry Ford Hospital study: Fewer infections with new heart-pump implant
7. Henry Ford Hospital: New left-side heart pump improves right-side heart function
8. Henry Ford Hospital study: Less prep needed for colonoscopy
9. Henry Ford Health System goes radical: Creating the hospital of the future
10. Henry Ford Hospital atudy: Hepatitis C infection doubles risk for kidney cancer
11. Henry Ford Hospital study: Shoulder function not fully restored after surgery
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2016)... ... April 29, 2016 , ... Dr. Robert Mondavi, one of the ... smiles. Cosmetic dentistry is a fast-growing field as more patients are discovering the many ... learn more about the options currently available to them and which ones might work ...
(Date:4/29/2016)... ... , ... Reltok Nasal Products proudly announces that Boston Medical Products, Inc., a ... throat specialty, has added the KOTLER NASAL AIRWAY™ to its diverse product line. , ... patented safety device secured by nasal surgeons onto the floor of the nasal passages, ...
(Date:4/29/2016)... ... April 29, 2016 , ... ... growth round of funding led by Eastside Partners, with participation from existing investor ... growing customer base and accelerate its technology and product roadmap. , ...
(Date:4/29/2016)... ... April 29, 2016 , ... Regenerative Medicine Solutions ... to Work employee satisfaction survey, earning them second place for Tampa’s Best Places to ... employees. , “This is a great accomplishment for our team,” says RMS Human ...
(Date:4/29/2016)... ... April 29, 2016 , ... The infertility specialists at HRC Fertility/Orange County (HRC/OC) ... Daniel A. Potter -- are proud of the recent release of their 2014 in ... SART published the latest verified data for 375 U.S. member clinics. *Preliminary ...
Breaking Medicine News(10 mins):
(Date:4/29/2016)... -- Glycotope GmbH, a clinical-stage immuno-oncology company ... of Dr. Alfredo Zurlo as Chief Medical ... many years clinical experience and a proven track record ... was at Mologen AG where he was Chief Medical ... Zurlo held various positions at F Hoffmann La Roche ...
(Date:4/28/2016)... 2016 Research and Markets has ... Products Market 2016-2020" report to their offering. ... The global plastic surgery products market is expected ... period 2016-2020. , ,The growing adoption of laser in ... of the market. Lasers are used to treat a ...
(Date:4/28/2016)... YORK , April 28, 2016 ... online consumer insights on healthcare, announced today that it ... their report Cool Vendor in Life Sciences, 2016, ... April 15, 2016.  The report focuses on life-science- oriented ... gain insight from patients and doctors, confirm medication ingestion, ...
Breaking Medicine Technology: